Weighing the benefits of screening for early-onset colorectal cancer The Lancet Gastroenterology & Hepatology + +... + +

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00270-5/fulltext?dgcid=raven_jbs_etoc_email Oct 2025 Volume 10Number 10p871-962 https://www.thelancet.com/journals/langas/issue/vol10no10/PIIS2468-1253(25)X0009-1 Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00129-3/abstract?dgcid=raven_jbs_etoc_feature_langas Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00128-1/abstract?dgcid=raven_jbs_etoc_feature_langas